secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acorda Therapeutics, Inc. (—)
CIK:        0001008848
Form:       8-K
Filed at:   2023-02-15T23:59:59+00:00
Accession:  0001193125-23-039919
Event type: regulatory
Sentiment:  negative
Materiality: 0.70
Item codes: 3.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acorda receives Nasdaq extension until June 20, 2023 to meet $1 bid price rule
------------------------------------------------------------------------------

- Nasdaq Hearings Panel grants extension to June 20, 2023 to regain compliance with $1 minimum bid price.
- To regain compliance, bid price must close at or above $1 for at least 10 consecutive trading days.
- If not achieved organically, company may effect a reverse stock split (1:2 to 1:20) authorized by shareholders in Nov 2022.
- CEO cites business plan focused on Inbrija growth, Ampyra maintenance, and fiscal discipline to drive organic compliance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1008848/000119312523039919/0001193125-23-039919-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1008848/000119312523039919/d462809d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-039919

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer